CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...
Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients
China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion...
Henlius Biotech Gains NMPA Approval for Phase I Trial of HLX60 in Solid Tumors and Lymphomas
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products...
PureID Medical Technology Secures RMB 100M Series B Funding
PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has...
Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results
China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...
Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma
China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a...
Salus Biomed Raises Over RMB 100M in Pre-Series A Financing
Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised...
Haisco Pharma’s Ciprofol Injection Gains NMPA Approval for Gynecology Use
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from...
ScienCare Pharma’s Naltrexone Implant Prioritized for Review by CDE
The Center for Drug Evaluation (CDE) website indicates that the market filing by China-based Shenzhen...
Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND)...
Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform
China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic...
Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer
China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...
Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...
Genor Biopharma Initiates First Patient Dosing for GB263T in China
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a...
Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study
China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...
Innovent Biologics Publishes Mazdutide Phase Ib Study Results for Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the results of the higher-dose cohorts...
Sihuan Pharma to Acquire Additional Stake in Heilongjiang Duoduo Pharma
China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931),...
NHSA Completes Expert Review for NRDL Price Negotiation Process
The National Healthcare Security Administration (NHSA) has released a notification indicating that the expert review...
BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving a positive opinion...
Kira Pharmaceuticals Gains NMPA Approval for Phase II Study of KP104 in PNH
Sino-US biotech Kira Pharmaceuticals has announced receiving approval from the National Medical Products Administration (NMPA)...